FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Antimicrob Agents Chemother / Relative activities of acyclovir and BW759 against Aujeszky&...
Antimicrobial agents and chemotherapy1983; 24(2); 221-226; doi: 10.1128/AAC.24.2.221

Relative activities of acyclovir and BW759 against Aujeszky’s disease and equine rhinopneumonitis viruses.

Abstract: Compound BW759 (9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine) was shown to be about 230 times more active than acyclovir (9-[2-hydroxyethoxymethyl]guanine) (ACV) against Equid herpesvirus type 1 infection in Syrian hamsters and was more effective against Aujeszky's disease in mice. The therapeutic superiority of BW759 over ACV was greater than expected from quantitative inhibitory results in tissue culture with these viruses. When administered to hamsters at dose rates sufficient to prevent any Equid herpesvirus type 1-induced mortality (100 mg of ACV per kg per day; 3 mg of BW759 per kg per day), BW759 inhibited viral multiplication, as judged by histopathological observations, clinical chemistry, and liver virus concentrations, to a greater extent than ACV. Compound BW759 was particularly effective when administered via the oral route. The reasons for the superiority of BW759 over ACV remain to be elucidated.
Get Full Text
Publication Date: 1983-08-01 PubMed ID: 6314886PubMed Central: PMC185141DOI: 10.1128/AAC.24.2.221Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates the comparative effectiveness of two antiviral compounds, BW759 and acyclovir (ACV), against Equid herpesvirus type 1 and Aujeszky’s disease. It was observed that BW759 displayed a significantly higher activity as compared to ACV, specifically in preventing infection in hamsters and treating Aujeszky’s disease in mice.

Comparison of BW759 and Acyclovir

  • The study aimed to compare the relative efficacy of two antiviral compounds – BW759 and acyclovir (ACV) – against two types of viruses: Equid herpesvirus type 1 that commonly infects horses and Aujeszky’s disease virus which is a cause of disease in swine.
  • In their experiments, the researchers discovered that BW759 displayed approximately 230 times more activity against the Equid herpesvirus type 1 compared to ACV. This meant that the compound was significantly more effective in preventing this type of viral infection in Syrian hamsters.
  • Moreover, BW759 was also found to be more effective in treating Aujeszky’s disease in mice, indicating a broader range of antiviral activity.

Therapeutic Superiority of BW759

  • The researchers observed that BW759’s superior therapeutic performance against these viruses exceeded the initial expectations based on quantitative inhibitory results performed in a tissue culture study.
  • When administered to hamsters in dosages sufficient to prevent mortality induced by Equid herpesvirus type 1, BW759 was more successful in inhibiting viral multiplication than ACV. This observation was based on a variety of evaluation methods including histopathological observations, clinical chemistry, and measured liver virus concentrations.
  • It was found to be notably effective when administered orally, adding a practical advantage.

Conclusions and Further Research

  • Although this study clearly demonstrated the superior effectiveness of BW759 over ACV in the treatment of Equid herpesvirus type 1 and Aujeszky’s disease, the underlying reasons for this superiority have yet to be fully understood.
  • These findings underline the need for further research to explore the mechanisms of action and potential applications of BW759 as an antiviral therapeutic agent.

Cite This Article

APA
Rollinson EA, White G. (1983). Relative activities of acyclovir and BW759 against Aujeszky’s disease and equine rhinopneumonitis viruses. Antimicrob Agents Chemother, 24(2), 221-226. https://doi.org/10.1128/AAC.24.2.221

Publication

Antimicrobial agents and chemotherapy
ISSN: 0066-4804
NlmUniqueID: 0315061
Country: United States
Language: English
Volume: 24
Issue: 2
Pages: 221-226

Researcher Affiliations

Rollinson, E A
    White, G

      MeSH Terms

      • Acyclovir / analogs & derivatives
      • Acyclovir / therapeutic use
      • Alkaline Phosphatase / analysis
      • Animals
      • Antiviral Agents / therapeutic use
      • Body Weight / drug effects
      • Cricetinae
      • Ganciclovir
      • Herpesviridae Infections / drug therapy
      • Herpesvirus 1, Equid
      • Liver / pathology
      • Male
      • Mesocricetus
      • Mice
      • Mice, Inbred Strains
      • Pseudorabies / drug therapy

      References

      This article includes 10 references
      1. Kemen MJ Jr. Clinical aspects of viral respiratory infections of horses.. J Am Vet Med Assoc 1975 Jan 1;166(1):85-8.
        pubmed: 162905
      2. Lieberman M, Pascale A, Schafer TW, Came PE. Effect of antiviral agents in equine abortion virus-infected hamsters.. Antimicrob Agents Chemother 1972 Feb;1(2):143-7.
        pubmed: 4376907doi: 10.1128/AAC.1.2.143google scholar: lookup
      3. Allen LB, Huffman JH, Revankar GR, Tolman RL, Simon LN, Robins RK, Sidwell RW. Efficacy of 9-beta-D-arabinofuranosylhypoxanthine 5'-monophosphate in therapy of equine abortion virus-induced hepatitis in hamsters.. Antimicrob Agents Chemother 1975 Oct;8(4):474-8.
        pubmed: 172009doi: 10.1128/AAC.8.4.474google scholar: lookup
      4. Aswell JF, Allen GP, Jamieson AT, Campbell DE, Gentry GA. Antiviral activity of arabinosylthymine in herpesviral replication: mechanism of action in vivo and in vitro.. Antimicrob Agents Chemother 1977 Aug;12(2):243-54.
        pubmed: 197886doi: 10.1128/AAC.12.2.243google scholar: lookup
      5. DOLL ER. Immunization against viral rhinopneumonitis of horses with live virus propagated in hamsters.. J Am Vet Med Assoc 1961 Dec 15;139:1324-30.
        pubmed: 13887043
      6. Collins P, Bauer DJ. The activity in vitro against herpes virus of 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine), a new antiviral agent.. J Antimicrob Chemother 1979 Jul;5(4):431-6.
        pubmed: 489491doi: 10.1093/jac/5.4.431google scholar: lookup
      7. Brigden D, Fiddian P, Rosling AE, Ravenscroft T. Acyclovir - a review of the preclinical and early clinical data of a new antiherpes drug.. Antiviral Res 1981 Nov;1(4):203-12.
        pubmed: 6280605doi: 10.1016/0166-3542(81)90011-5google scholar: lookup
      8. Weinmaster GA, Misra V, McGuire R, Babiuk LA, DeClercq E. Bovid herpesvirus type-1 (infectious bovine rhinotracheitis virus)-induced thymidine kinase.. Virology 1982 Apr 15;118(1):191-201.
        pubmed: 7080438doi: 10.1016/0042-6822(82)90332-4google scholar: lookup
      9. Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2.. Antimicrob Agents Chemother 1982 Jul;22(1):55-61.
        pubmed: 6289741doi: 10.1128/AAC.22.1.55google scholar: lookup
      10. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 9-(2-hydroxyethoxymethyl) guanine activity against viruses of the herpes group.. Nature 1978 Apr 13;272(5654):583-5.
        pubmed: 205792doi: 10.1038/272583a0google scholar: lookup

      Citations

      This article has been cited 7 times.
      1. Kelley JL. Chapter 12. Antiviral Agents. Annu Rep Med Chem 1984;19:117-126.
        doi: 10.1016/S0065-7743(08)60688-0pubmed: 32336813google scholar: lookup
      2. Tallmadge RL, Žygelytė E, Van de Walle GR, Kristie TM, Felippe MJB. Effect of a Histone Demethylase Inhibitor on Equine Herpesvirus-1 Activity In Vitro. Front Vet Sci 2018;5:34.
        doi: 10.3389/fvets.2018.00034pubmed: 29594155google scholar: lookup
      3. Maxwell LK, Bentz BG, Gilliam LL, Ritchey JW, Pusterla N, Eberle R, Holbrook TC, McFarlane D, Rezabek GB, Meinkoth J, Whitfield C, Goad CL, Allen GP. Efficacy of the early administration of valacyclovir hydrochloride for the treatment of neuropathogenic equine herpesvirus type-1 infection in horses. Am J Vet Res 2017 Oct;78(10):1126-1139.
        doi: 10.2460/ajvr.78.10.1126pubmed: 28945127google scholar: lookup
      4. Fraser-Smith EB, Eppstein DA, Marsh YV, Matthews TR. Enhanced efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine in combination with beta-interferon against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother 1984 May;25(5):563-5.
        doi: 10.1128/AAC.25.5.563pubmed: 6610387google scholar: lookup
      5. Fraser-Smith EB, Smee DF, Matthews TR. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother 1983 Dec;24(6):883-7.
        doi: 10.1128/AAC.24.6.883pubmed: 6607031google scholar: lookup
      6. Cheng YC, Grill SP, Dutschman GE, Frank KB, Chiou JF, Bastow KF, Nakayama K. Effects of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new antiherpesvirus compound, on synthesis of macromolecules in herpes simplex virus-infected cells. Antimicrob Agents Chemother 1984 Sep;26(3):283-8.
        doi: 10.1128/AAC.26.3.283pubmed: 6095751google scholar: lookup
      7. Field HJ, Awan AR. Effective chemotherapy of equine herpesvirus 1 by phosphonylmethoxyalkyl derivatives of adenine demonstrated in a novel murine model for the disease. Antimicrob Agents Chemother 1990 May;34(5):709-17.
        doi: 10.1128/AAC.34.5.709pubmed: 2163242google scholar: lookup
      Subscribe to our newsletter
      Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.